Meeting News CoverageVideo

VIDEO: Expert discusses the biologics of asthma

Geoffrey L. Chupp, MD, director of the Yale Center for Asthma and Airways Disease, discusses the biologics of asthma.

Chupp says that with drugs in development targeting the Interluekin-5 pathway as well as Interluekin-13, patients with non-allergic asthma will have other options for treatment.

“The addition of additional agents is good for patients with the disease and good in general because it is increasing awareness about the importance of achieving control in your patients and what lack of control means and it is providing other opportunities for patients that don't fall into the allergic category,” Chupp told Healio.com/Allergy.

See more from American Thoracic Society International Conference